EW News and Press, Edwards Lifesciences Corporation From 02/06/24

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...

2024-02-06 01:10:00 ET Summary Some big tech results fizzled, but there were two standouts last week. Nine S&P 500® companies have outlier earnings dates this week - MCD, IEX, EW, MAA, MCK, HSY, COP, TROW, CTLT. 1,558 companies are expected to report during the second...

2024-02-05 17:05:31 ET More on Edwards Lifesciences Edward Lifesciences: Still Not A Buy But Getting Closer Edwards Lifesciences: Undervalued With A Substantial Upside Potential Seeking Alpha’s Quant Rating on Edwards Lifesciences Read the full artic...

2024-02-02 12:20:25 ET More on Edwards Lifesciences Edward Lifesciences: Still Not A Buy But Getting Closer Edwards Lifesciences: Undervalued With A Substantial Upside Potential Edwards gets FDA okay for Evoque tricuspid valve replacement system Edwards Lifes...

2024-02-02 10:51:42 ET More on Edwards Lifesciences Edward Lifesciences: Still Not A Buy But Getting Closer Edwards Lifesciences: Undervalued With A Substantial Upside Potential Edwards Lifesciences provides 2024 outlook, OKs additional $1B stock buyback Edwa...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicat...

2024-01-31 15:33:55 ET More on Boston Scientific, Stryker, etc. Boston Scientific Corporation (BSX) Q4 2023 Earnings Call Transcript Stryker Corporation (SYK) Q4 2023 Earnings Call Transcript Boston Scientific: Portfolio Updates Driving Top-Line Growth Boston...

2024-01-31 08:05:00 ET Summary The Ithaka Group is an independent investment boutique that specializes in managing high-quality, concentrated growth equity portfolios. During the fourth quarter Ithaka’s portfolio outperformed in a strong market, rising 18.4% vs the R1G risi...

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial ...

2024-01-22 11:29:07 ET More on S&P 500 Index: S&P 500 Sets New Record High As Investors Potentially Shift Focus To Q2 2024 Market Rally Met With Outflows S&P 500: The 'Pump' Is Underway - Watch Out For The 'Dump' S&P won't get the helping hand...